Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Farletuzumab||MORAb-003||FOLR1-targeted Therapy 19||Farletuzumab (MORab003) is a monoclonal antibody that binds to FolR1, resulting in decreased interaction between FolR1 and Lyn, as well as increased antibody-dependent cytotoxicity and tumor cell lysis (PMID: 26063635, PMID: 30268765).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02289950||Phase II||Farletuzumab||A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer||Completed||USA | ITA | GBR | ESP | DEU | BEL||1|